IP Library Granted Patent US 12,514,608
Granted Patent B2
US 12,514,608 · App. 16/797,585 · Granted Jan 6, 2026

Intravascular catheter balloon device

Inventor: John P. Pigott (Sylvania, OH)
Assignee: VentureMed Group, Inc.
A61B17/320725A61B2017/00893A61B2017/22061A61B2017/320004A61B2017/320008A61M2025/109
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,608
App. No.
16/797,585
Granted
Jan 6, 2026
Kind
B2
Abstract

Methods for fragmenting atherosclerotic material within a zone of attention within a blood vessel are provided. An intravascular catheter device includes a balloon and a plurality of incising devices spaced apart about an outer surface of the balloon and extending parallel with a longitudinal axis of the balloon. The balloon is manipulated along a guide wire to a distal portion of the zone of attention. The balloon is inflated and retracted along the zone of attention to incise and fragment the atherosclerotic material. The balloon is deflated.

Claims (90)

1 . A method for fragmenting material within a zone of attention within a blood vessel, said method comprising the steps of:

providing an intravascular catheter device comprising a balloon, incising devices spaced apart about an outer surface of the balloon, wherein said incising devices extend along a longitudinal axis of the balloon, and a valve located fluidly upstream of an entrance to the balloon for controlling flow of an inflation fluid into and out of a portion of the intravascular catheter device fluidly downstream of the valve, where said portion of the intravascular catheter device includes the balloon;

advancing the balloon to a distal portion of the zone of attention while in a deflated state;

performing a therapy at the zone of attention by:

inflating the balloon wherein the step of inflating the balloon includes operating the valve such that fluid may pass into the balloon;

after inflating the balloon, closing the valve such that fluid may not pass into or out of the balloon; and

while the balloon remains inflated, retracting the balloon along the zone of attention to incise the material; and

subsequently deflating the balloon, including operating the valve such that fluid may leave the balloon; and

while the balloon is deflated, either re-advancing the balloon in the deflated state to the distal portion of the zone of attention for performing additional therapy or removing the balloon from the zone of attention.

2 . The method of claim 1 further comprising the steps of:

providing an angioplasty balloon;

manipulating the angioplasty balloon to the zone of attention;

inflating the angioplasty balloon to compress the fragmented material, wherein the angioplasty balloon is inflated to a higher pressure than the balloon; and

deflating the angioplasty balloon.

3 . The method of claim 1 wherein:

the balloon is inflated to a pressure configured to place the incising devices in contact with the material without compressing the material.

4 . The method of claim 1 further comprising the steps of:

rotating the balloon prior to re-advancing the balloon in the deflated state to the distal portion of the zone of attention;

inflating the balloon an additional time;

retracting the balloon along the zone of attention to incise the material while the balloon is inflated an additional time so as to incise different portions of the material; and

deflating the balloon an additional time.

5 . The method of claim 1 wherein:

said balloon comprises a cylindrically shaped portion, when inflated, and a tapered portion on each end of the cylindrically shaped portion;

said incising devices are secured about an outer surface of the cylindrically shaped portion of said balloon; and

said incising devices extend parallel with the longitudinal axis of the balloon.

6 . The method of claim 5 wherein:

each of said incising devices comprise a blade;

each of said blades comprise an arcuate shape and extend away from the outer surface; and

each of said blades are positioned at a distal portion of said cylindrically shaped portion of said balloon.

7 . The method of claim 1 further comprising the steps of:

providing a sheath and a tip member;

providing a coating comprising at least one pharmaceutical at the balloon;

providing a lubricious material between said balloon and an inner surface of said sheath;

placing the sheath in a closed position such that said sheath abuts said tip member to form a watertight connection; and

placing the sheath in an opened position to expose the coating and release or activate the pharmaceutical.

8 . The method of claim 1 further comprising the steps of:

manipulating a guide wire to the distal portion of the zone of attention, wherein the step of advancing the balloon to the distal portion of the zone of attention comprises the sub-steps of placing the balloon atop the guidewire and manipulating the balloon along the guide wire.

9 . The method of claim 1 wherein:

the material comprises atherosclerotic material.

10 . The method of claim 1 wherein:

the valve is operable between an open and a closed position;

when closed, the valve prevents flow of the inflation fluid into and out of the portion of the intravascular catheter device fluidly downstream of the valve; and

when open, the valve allows flow of the inflation fluid into and out of the portion of the intravascular catheter device fluidly downstream of the valve.

11 . The method of claim 1 :

wherein the step of inflating the balloon includes operating the valve such that fluid may only pass into the balloon.

12 . The method of claim 1 further comprising:

maintaining the valve in the closed position during the step of retracting the balloon along the zone of attention to incise the material.

13 . A method for fragmenting atherosclerotic material within a zone of attention within a blood vessel, said method comprising the steps of:

providing an intravascular catheter device comprising a handle assembly comprising an inflation device, a valve configured to control a flow of inflation fluid, a catheter tube extending from said handle assembly and configured to accommodate the inflation fluid, a balloon connected to a distal portion of, and in fluid communication with, said catheter tube and comprising blades spaced apart about an outer surface of the balloon, wherein said blades are oriented to extend parallel with a longitudinal axis of the balloon;

manipulating a guide wire to a distal end of the zone of attention;

manipulating the intravascular catheter device, while in a deflated state, along the guide wire to the distal end of the zone of attention;

inflating the balloon to an inflated state where the blades contact the atherosclerotic material;

closing the valve after inflating the balloon to the inflated state;

performing a therapy by retracting the balloon, while the balloon is maintained in the inflated state, along the zone of attention to incise and fragment the atherosclerotic material, and subsequently:

deflating the balloon, including by opening the valve;

removing the balloon from the zone of attention;

manipulating an angioplasty balloon to a location within the zone of attention; and

inflating the angioplasty balloon to compress the incised and fragmented atherosclerotic material, wherein the angioplasty balloon is inflated to a higher pressure than the balloon.

14 . The method of claim 13 further comprising the steps of:

providing a sheath and a tip member;

providing a coating at the balloon, said coating comprising a material comprising at least one pharmaceutical agent;

placing the sheath in a closed position such that said sheath abuts said tip member to form a watertight connection about the balloon to prevent the at least one pharmaceutical agent from premature elution; and

placing the sheath in an opened position to expose the coating and activate and release the at least one pharmaceutical agent.

15 . A method for fragmenting atherosclerotic material within a zone of attention within a blood vessel, said method comprising the steps of:

providing an intravascular catheter device comprising a balloon, incising devices spaced apart about a circumference of an outer surface of the balloon and extending along a longitudinal axis of the balloon, and a valve fluidly upstream of an entrance to the balloon for controlling flow of an inflation fluid into and out of the balloon;

providing an angioplasty device comprising an angioplasty balloon;

manipulating the intravascular catheter device, while said balloon is in a deflated state, to a distal end of the zone of attention;

performing a first therapy by:

inflating the balloon to a first pressure, thereby placing the incising devices in contact with the atherosclerotic material, and closing the valve; and

retracting the balloon along the zone of attention at least once to incise and fragment the atherosclerotic material while the balloon is inflated; and

after completing performance of the first therapy:

manipulating the angioplasty device to a location within the zone of attention; and

performing a second therapy by inflating the angioplasty balloon to a second pressure sufficient to compress the incised and fragmented atherosclerotic material;

wherein said second pressure is higher than said first pressure, and wherein said second pressure is higher than said first pressure and is lower than would be required to compress said atherosclerotic material in a non-incised and non-fragmented state.

16 . The method of claim 15 further comprising the steps of:

providing a coating at the balloon, said coating comprising at least one pharmaceutical agent;

providing a tip member and a sheath at said intravascular catheter device, wherein said sheath is configured to selectively abut said tip member to form a watertight connection about said balloon; and

placing the sheath in an opened position, when said balloon is located within said zone of attention, to activate and release the at least one pharmaceutical agent.

17 . A method for fragmenting material within a zone of attention within a blood vessel, said method comprising:

providing an intravascular catheter device comprising a sheath, a balloon, incising devices spaced apart about an outer surface of the balloon, and a valve located fluidly upstream from an entrance into the balloon, wherein said incising devices extend along a longitudinal axis of the balloon, and wherein said sheath is configured for sliding movement to selectively cover said balloon and said incising devices;

manipulating the balloon to a distal portion of the zone of attention while said balloon is in a deflated state and covered by said sheath;

unsheathing the balloon and said incising devices;

while unsheathed, inflating the balloon to a pressure thereby placing the incising devices in contact with the material, and operating the valve into a closed position;

retracting the balloon along the zone of attention while the balloon is inflated, thereby incising the material while the balloon is inflated and unsheathed;

deflating the balloon; and

re-sheathing the balloon and incising devices.

18 . The method of claim 17 further comprising:

providing a tip member and a coating on said balloon comprising at least one fluid-activated pharmaceutical, wherein sheathing the balloon comprising abutting the tip member to the sheath to form a watertight connection, and wherein unsheathing the balloon exposes the coating to activate the at least one pharmaceutical.

19 . The method of claim 17 wherein:

the material comprises atherosclerotic material.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: VENTUREMED GROUP, INC.
To: ENDEAVOUR MEDTECH GROWTH LP; RIVERVEST VENTURE FUND III, L.P.; RIVERVEST VENTURE FUND III (OHIO), L.P.
Reel/Frame 065991/0794 →
SECURITY INTEREST Recorded Oct 29, 2021
From: VENTUREMED GROUP, INC.
To: ENDEAVOUR MEDTECH GROWTH LP; RIVERVEST VENTURE FUND III, L.P.; RIVERVEST VENTURE FUND III (OHIO), L.P.
Reel/Frame 057961/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2020
From: PIGOTT, JOHN P.
To: VENTUREMED GROUP, INC.
Reel/Frame 053905/0816 →
Continuity (3)
Continuation 14991493 · Jan 8, 2016
Provisional Application 62102755 · Jan 13, 2015
Related Publication 20200197041A1 · Jun 25, 2020
References Cited (182)
US 2655154A · Richter · 1953 [cited by applicant]
US 3557794A · Van Patten · 1971 [cited by applicant]
US 3704711A · Park · 1972 [cited by applicant]
US 4273128A · Banning · 1981 [cited by applicant]
US 4292974A · Fogarty et al. · 1981 [cited by applicant]
US 4654027A · Dragan · 1987 [cited by examiner]
US 5030201A · Palestrant · 1991 [cited by applicant]
US 5074871A · Groshong · 1991 [cited by applicant]
US 5100425A · Fischell et al. · 1992 [cited by applicant]
US 5154724A · Andrews · 1992 [cited by applicant]
US 5156610A · Reger · 1992 [cited by applicant]
US 5178625A · Groshong · 1993 [cited by applicant]
US 5190525A · Oswald et al. · 1993 [cited by applicant]
US 5211651A · Reger et al. · 1993 [cited by applicant]
US 5224945A · Pannek, Jr. · 1993 [cited by applicant]
US 5224949A · Gomringer · 1993 [cited by examiner]
US 5244619A · Burnham · 1993 [cited by applicant]
US 5246421A · Saab · 1993 [cited by applicant]
US 5250060A · Carbo et al. · 1993 [cited by applicant]
US 5282484A · Reger · 1994 [cited by applicant]
US 5312427A · Shturman · 1994 [cited by applicant]
US 5318576A · Plassche, Jr. et al. · 1994 [cited by applicant]
US 5514093A · Ellis et al. · 1996 [cited by applicant]
US 5591194A · Berthiaume · 1997 [cited by applicant]
US 5658309A · Berthiaume et al. · 1997 [cited by applicant]
US 5665098A · Kelly et al. · 1997 [cited by applicant]
US 5676654A · Ellis et al. · 1997 [cited by applicant]
US 5697944A · Lary · 1997 [cited by examiner]
US 5697948A · Marin et al. · 1997 [cited by applicant]
US 5728067A · Enger · 1998 [cited by applicant]
US 5728123A · Lemelson et al. · 1998 [cited by applicant]
US 5733296A · Rogers et al. · 1998 [cited by applicant]
US 5766192A · Zacca · 1998 [cited by applicant]
US 5792158A · Lary · 1998 [cited by applicant]
US 5800450A · Lary et al. · 1998 [cited by applicant]
US 5836868A · Ressemann et al. · 1998 [cited by applicant]
US 5876448A · Thompson et al. · 1999 [cited by applicant]
US 5961536A · Mickley et al. · 1999 [cited by applicant]
US 5968064A · Selmon et al. · 1999 [cited by applicant]
US 6071287A · Verbeek · 2000 [cited by applicant]
US 6120515A · Rogers et al. · 2000 [cited by applicant]
US 6129708A · Enger · 2000 [cited by applicant]
US 6165187A · Reger · 2000 [cited by applicant]
US 6217549B1 · Selmon et al. · 2001 [cited by applicant]
US 6258108B1 · Lary · 2001 [cited by applicant]
US 6270489B1 · Wise et al. · 2001 [cited by applicant]
US 6283947B1 · Mirzaee · 2001 [cited by applicant]
US 6527740B1 · Jackson et al. · 2003 [cited by applicant]
US 6599267B1 · Ray et al. · 2003 [cited by applicant]
US 6692466B1 · Chow et al. · 2004 [cited by applicant]
US 6695863B1 · Ramzipoor et al. · 2004 [cited by applicant]
US 6719773B1 · Boucher et al. · 2004 [cited by applicant]
US 6884257B1 · Cox · 2005 [cited by applicant]
US 7108704B2 · Trerotola · 2006 [cited by applicant]
US 7131981B2 · Appling et al. · 2006 [cited by applicant]
US 7279002B2 · Shaw et al. · 2007 [cited by applicant]
US 7303572B2 · Melsheimer et al. · 2007 [cited by applicant]
US 7517352B2 · Evans et al. · 2009 [cited by applicant]
US 7686824B2 · Konstantino et al. · 2010 [cited by applicant]
US 7691086B2 · Tkebuchava · 2010 [cited by applicant]
US 7708753B2 · Hardert · 2010 [cited by applicant]
US 7850685B2 · Kunis et al. · 2010 [cited by applicant]
US 7850710B2 · Huss · 2010 [cited by applicant]
US 7887557B2 · Kelley et al. · 2011 [cited by applicant]
US 7955350B2 · Konstantino et al. · 2011 [cited by applicant]
US 8323307B2 · Hardert · 2012 [cited by applicant]
US 8328829B2 · Olson · 2012 [cited by applicant]
US 8348987B2 · Eaton · 2013 [cited by applicant]
US 8366661B2 · Weber et al. · 2013 [cited by applicant]
US 8398662B2 · Granada et al. · 2013 [cited by applicant]
US 8454636B2 · Konstantino et al. · 2013 [cited by applicant]
US 8500789B2 · Wuebbeling et al. · 2013 [cited by applicant]
US 8685049B2 · Schur et al. · 2014 [cited by applicant]
US 8685050B2 · Schur et al. · 2014 [cited by applicant]
US 8702736B2 · Schur et al. · 2014 [cited by applicant]
US 8740849B1 · Fischell et al. · 2014 [cited by applicant]
US 8870816B2 · Chambers et al. · 2014 [cited by applicant]
US 9079000B2 · Hanson et al. · 2015 [cited by applicant]
US 9192747B2 · Hardert · 2015 [cited by applicant]
US 9282991B2 · Schur et al. · 2016 [cited by applicant]
US 9314329B2 · Dickinson et al. · 2016 [cited by applicant]
US 9364255B2 · Weber · 2016 [cited by applicant]
US 9364284B2 · Groff et al. · 2016 [cited by applicant]
US 9510901B2 · Steinke et al. · 2016 [cited by applicant]
US 9532798B2 · Schur et al. · 2017 [cited by applicant]
US 9545263B2 · Lenihan et al. · 2017 [cited by applicant]
US 9592386B2 · Mathur et al. · 2017 [cited by applicant]
US 9604036B2 · Burton et al. · 2017 [cited by applicant]
US 10842971B2 · Iwano et al. · 2020 [cited by applicant]
US 10874837B2 · Iwano et al. · 2020 [cited by applicant]
US 20010007059A1 · Mirzaee · 2001 [cited by applicant]
US 20020010489A1 · Grayzel et al. · 2002 [cited by applicant]
US 20020143350A1 · Heitzmann et al. · 2002 [cited by applicant]
US 20030040770A1 · Radisch, Jr. · 2003 [cited by examiner]
US 20030069547A1 · Gonon · 2003 [cited by applicant]
US 20030125756A1 · Shturman et al. · 2003 [cited by applicant]
US 20030144677A1 · Lary · 2003 [cited by applicant]
US 20040034384A1 · Fukaya · 2004 [cited by applicant]
US 20040098014A1 · Flugelman · 2004 [cited by applicant]
US 20040122457A1 · Weber · 2004 [cited by applicant]
US 20040193196A1 · Appling · 2004 [cited by examiner]
US 20040204738A1 · Weber et al. · 2004 [cited by applicant]
US 20040267345A1 · Lorenzo et al. · 2004 [cited by applicant]
US 20050055077A1 · Marco et al. · 2005 [cited by applicant]
US 20050149102A1 · Radisch, Jr. et al. · 2005 [cited by applicant]
US 20050149159A1 · Andreas et al. · 2005 [cited by applicant]
US 20050151304A1 · Boelens et al. · 2005 [cited by applicant]
US 20050240176A1 · Oral et al. · 2005 [cited by applicant]
US 20060089637A1 · Werneth et al. · 2006 [cited by applicant]
US 20060106413A1 · Bence · 2006 [cited by examiner]
US 20060111736A1 · Kelley · 2006 [cited by applicant]
US 20060116701A1 · Crow · 2006 [cited by applicant]
US 20060184191A1 · O'Brien · 2006 [cited by applicant]
US 20070005093A1 · Cox · 2007 [cited by applicant]
US 20070060863A1 · Goeken et al. · 2007 [cited by applicant]
US 20070106215A1 · Olsen et al. · 2007 [cited by applicant]
US 20070156225A1 · George et al. · 2007 [cited by applicant]
US 20070181157A1 · Dadourian · 2007 [cited by applicant]
US 20080140051A1 · Bei et al. · 2008 [cited by applicant]
US 20080294116A1 · Wolter et al. · 2008 [cited by applicant]
US 20080300594A1 · Goto · 2008 [cited by applicant]
US 20080300610A1 · Chambers · 2008 [cited by applicant]
US 20090099583A1 · Butterfield et al. · 2009 [cited by applicant]
US 20090105686A1 · Snow et al. · 2009 [cited by applicant]
US 20090192508A1 · Laufer et al. · 2009 [cited by applicant]
US 20090204068A1 · Nguyen et al. · 2009 [cited by applicant]
US 20090306690A1 · Rivers et al. · 2009 [cited by applicant]
US 20090312807A1 · Boudreault et al. · 2009 [cited by applicant]
US 20100010521A1 · Kurrus · 2010 [cited by applicant]
US 20100023035A1 · Kontos · 2010 [cited by applicant]
US 20100121270A1 · Gunday et al. · 2010 [cited by applicant]
US 20100168737A1 · Grunewald · 2010 [cited by applicant]
US 20100168778A1 · Braido · 2010 [cited by applicant]
US 20100228333A1 · Drasler · 2010 [cited by examiner]
US 20100330147A1 · Hossainy et al. · 2010 [cited by applicant]
US 20110060182A1 · Kassab et al. · 2011 [cited by applicant]
US 20110152683A1 · Gerrans et al. · 2011 [cited by applicant]
US 20110160645A1 · Sutermeister et al. · 2011 [cited by applicant]
US 20110184447A1 · Leibowitz et al. · 2011 [cited by applicant]
US 20110288479A1 · Burton · 2011 [cited by applicant]
US 20120053485A1 · Bloom · 2012 [cited by applicant]
US 20120143054A1 · Eaton et al. · 2012 [cited by applicant]
US 20120150142A1 · Weber et al. · 2012 [cited by applicant]
US 20120157988A1 · Stone et al. · 2012 [cited by applicant]
US 20120172901A1 · Manderfeld et al. · 2012 [cited by applicant]
US 20120191111A1 · Aggerholm · 2012 [cited by examiner]
US 20130066346A1 · Pigott · 2013 [cited by examiner]
US 20130131594A1 · Bonnette et al. · 2013 [cited by applicant]
US 20130150874A1 · Kassab · 2013 [cited by applicant]
US 20130237950A1 · Gianotti et al. · 2013 [cited by applicant]
US 20130253467A1 · Gianotti et al. · 2013 [cited by applicant]
US 20140277002A1 · Grace · 2014 [cited by applicant]
US 20140364896A1 · Consigny · 2014 [cited by applicant]
US 20150133978A1 · Paul, Jr. · 2015 [cited by applicant]
US 20170056048A1 · Erpen · 2017 [cited by applicant]
US 20170079679A1 · Pigott · 2017 [cited by applicant]
US 20170238960A1 · Hatta et al. · 2017 [cited by applicant]
US 20180177985A1 · Nakagawa et al. · 2018 [cited by applicant]
US 20190307992A1 · Haverkost et al. · 2019 [cited by applicant]
US 20210023347A1 · Iwano et al. · 2021 [cited by applicant]
WO 8102109A1 · 1981 [cited by applicant]
WO 9502370A2 · 1995 [cited by applicant]
WO 0727194A1 · 1996 [cited by applicant]
WO 1996039997A2 · 1996 [cited by applicant]
WO 9918862A1 · 1999 [cited by applicant]
WO 02078511A2 · 2002 [cited by applicant]
WO 02078511A3 · 2002 [cited by applicant]
WO 2007095125A2 · 2007 [cited by applicant]
WO 2013159066A1 · 2013 [cited by applicant]
WO 2014106226A2 · 2014 [cited by applicant]
WO 2014142801A1 · 2014 [cited by applicant]
WO 2015190578A1 · 2015 [cited by applicant]
WO 2015195606A1 · 2015 [cited by applicant]
WO 2016210167A1 · 2016 [cited by applicant]
Cardiovascular Systems Inc., Diamondback 360 Coronary Orbital Atherectomy System, http://www.csi360.com/products/coronary-diamondback-360-coronary-orbital-atherectomy-system-crowns/, 2016. [cited by applicant]
Boston Scientific Corporation, FilterWire EZ, Embolic Protection System for Carotid Arteries, Sep. 2015, http://www.bostonscientific.com/en-US/products/embolic-protection/filterwire-ez-embolic-protection-system.html. [cited by applicant]
International Search Report, Application No. PCT/US2012/055079, dated Jan. 31, 2013. [cited by applicant]
Boston Scientific, Rotablator Rotational Atherectomy System, http://www.bostonscientific.com/en-US/products/plaque-modification/rotablator-rotational-atherectomy-system.html, 2017. [cited by applicant]
Covidien, SpiderFX Embolic Protection Device, 2015, https://www.ev3.net/peripheral/US/embolic-protection/spiderfxtrade-embolic-protection-device.htm. [cited by applicant]
Boston Scientific, Sterling 0.018″ Balloon Catheter, Jun. 2015. [cited by applicant]
Ham, S. et al., Safety of Carbon Dioxide Digital Subtraction Angiography, Archives of Surgery, Dec. 2011. [cited by applicant]
Alexander, J., CO2 Angiography in Lower Extremity Arterial Disease, Endovascular Today, Sep. 2011, pp. 27-34. [cited by applicant]